Reference
Haghikia A, et al. Severe B-cell-mediated CNS disease secondary to alemtuzumab therapy. Lancet Neurology 16: 104-106, No. 2, Feb 2017. Available from: URL: http://doi.org/10.1016/S1474-4422%2816%2930382-9 - Germany
Rights and permissions
About this article
Cite this article
Alemtuzumab. Reactions Weekly 1643, 19 (2017). https://doi.org/10.1007/s40278-017-27492-4
Published:
Issue Date:
DOI: https://doi.org/10.1007/s40278-017-27492-4